Retraction Notice to: Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF.

(Molecular Therapy 26, 755–773; March 2018) This article has been retracted at the request of the Editor-in-Chief. Similarities were found between images in this article and in two other articles: miRNA-337-3p inhibits gastric cancer progression through repressing myeloid zinc finger 1-facilitated expression of matrix metalloproteinase 14 (Zheng et al., 2016, Oncotarget 7, 40314-40328, https://doi.org/10.18632/oncotarget.9739) and HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression (Song et al., 2020, J. Hematol. Oncol. 13, 24, https://doi.org/10.1186/s13045-020-00857-7). Reader concerns were initially reported in a Pubpeer thread (https://pubpeer.com/publications/8027ACB199BDBD3A6228F65E2120CE). Image analysis performed by the editorial office confirmed the findings of image duplication in Figures 2B, 6B, 8E, and 8F of the Molecular Therapy article. This reuse (and in part misrepresentation) of data without appropriate attribution represents a severe abuse of the scientific publishing system. The authors disagree with the retraction and maintain that the conclusions of the paper are unaffected. The retraction notice was undeliverable to two authors (Dan Li and Dandan Huang). RETRACTED: Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCFZhao et al.Molecular TherapyDecember 22, 2017In BriefThis article has been retracted: please see Elsevier Policy on Article Withdrawal ( https://www.elsevier.com/locate/withdrawalpolicy ). Full-Text PDF Open Archive